Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

Virology

Volumn 230, Issue 2, 1997, Pages 217-227

  Gale Jr , Michael J ^a   Korth, Marcus J ^a   Tang, Norina M ^a   Tan, Seng Lai ^a   Hopkins, Deborah A ^a   Dever, Thomas E ^b   Polyak, Stephen J ^c   Gretch, David R ^c   Katze, Michael G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Pacific Medical Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PROTEIN KINASE; VIRUS PROTEIN;

ARTICLE; DRUG RESISTANCE; ENZYME INHIBITION; ESCHERICHIA COLI; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS MUTANT;

ESCHERICHIA COLI; HEPATITIS C VIRUS; NON-A, NON-B HEPATITIS VIRUS;

EID: 0343924357     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8493     Document Type: Article

References (64)

1. Alter M. Epidemiology of hepatitis C in the west. Semin. Liver Dis. 15:1995;5-14.
2. Barber G. N., Wambach M., Thompson S., Jagus R., Katze M. G. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol. Cell Biol. 15:1995;3138-3146.
3. Beattie E., Tartaglia J., Paoletti E. Vaccinia virus-encoded elF-2 alpha homolog abrogates the antiviral effect of interferon. Virology. 183:1991;419-422.
4. --. Virology. 210:1995;254-263.
5. Berger J., Hauber J., Hauber R., Gelger R., Cullen B. R. Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. Gene. 66:1988;1-10.
6. Bisceglie A. M. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis. 15:1995;64-69.
7. Bossemeyer D. Protein kinases - Structure and function. FEBS. Lett. 369:1995;57-61.
8. Bukh J., Miller R., Purcell R. Genetic heterogeneity of hepatits C virus: Quasispecies and genotypes. Semin. Liver Dis. 15:1995;41-63.
9. Cao J., Geballe A. P. Mutational analysis of the translational signal in the human cytomegalovirus gpUL4 (gp48) transcript leader by retroviral infection. Virology. 205:1994;151-160.
10. Carroll K., Elroy-Stein O., Moss R., Jagus R. Recombinant vaccinia virus K3L gene product prevents activation of dsRNA dependent eIF-2 kinase. J. Biol. Chem. 268:1993;12837-12842.
11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
12. M. J. Clemens, 1996, Translational Control, 139, 172, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
13. Cullen B. R. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 152:1987;684-704.
14. Cuthbert J. A. Hepatitis C: Progress and problems. Clin. Microbiol. Rev. 7:1994;505-532.
15. Davidson F., Simmonds P., Ferguson J., Jarvis L., Dow B., Follet E., Seed C., Krusius T., Lin C., Medgyesi G. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J. Gen. Virol. 76:1995;1197-1204.
16. Dever T. E., Chen J. J., Barber G. N., Cigan A. M., Feng L., Donahue T. F., London I. M., Katze M. G., Hinnebusch A. G. Mammalian eIF-2α kinases functionally substitute for GCN2 and stimulate GCN4 translation in yeast. Proc. Natl. Acad. Sci. USA. 90:1993;4616-4620.
17. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96:1995;224-230.
18. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Maruno F., Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:1996;77-81.
19. Fields S., Song O. A novel genetic system to detect protein-protein interactions. Nature. 340:1989;245-246.
20. Fried M., Hoofnagle J. Therapy of hepatitis C. Semin. Liver Dis. 15:1995;82-91.
21. Galabru J., Hovanessian A. G. Autophosphorylation of the protein kinase dependent on double-stranded RNA. J. Biol. Chem. 262:1987;15538-15544.
22. IPK. Mol. Cell. Biol. 16:1996;4172-4181.
23. Garfinkel M. S., Katze M. G. Translational control by influenza virus. Selective translation is mediated by sequences within the viral mRNA 5′-untranslated region. J. Biol. Chem. 268:1993;22223-22226.
24. Giantini M., Shatkin M. Stimulation of chloramphenicol acetyltransferase mRNA translation by reovirus capsid polypeptide σ3 in cotransfected COS cells. J. Virol. 63:1989;2415-2421.
25. Grakoui A., Wychowski C., Lin C., Feinstone S., Rice C. M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Gen. Virol. 67:1993;1385-1395.
26. Gretch D., Wilson J., Carithers R., dela Rosa C., Han J., Corey L. Detection of hepatits C virus RNA: Comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR. J. Clin. Microsc. 31:1993;289-291.
27. Hanks S. K., Quinn A. M., Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
28. Hershey J. W. B. Translational control in mammalian cells. Annu. Rev. Biochem. 60:1991;717-755.
29. Hoofnagle J. H. Therapy of acute and chronic viral hepatitis. Adv. Intern. Med. 39:1994;241-275.
30. Iino S., Hino K., Yasuda K. Current state of interferon therapy for chronic hepatitis C. Intervirology. 37:1994;87-100.
31. Kaneko T., Tanji Y., Satoh S., Hijikata M., Asabe S., Kimura K., Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205:1994;302-326.
32. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., Shimotohno K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA. 87:1990;9524-9528.
33. r. EMBO J. 6:1987;689-697.
34. Katze M. G., Wambach M., Wong M.-L., Garfinkel M. S., Meurs E., Chong K. L., Williams B. R. G., Hovanessian A. G., Barber G. N. Functional expression of interferon-induced, dsRNA activated 68,000 Mr protein kinase in a cell-free system. Mol. Cell. Biol. 11:1991;5497-5505.
35. r. Semin. Virol. 4:1993;259-268.
36. Katze M. G. Regulation of the interferon-induced PKR: Can viruses cope? Trends Microbiol. 3:1995;75-78.
37. Kaufman R. J., Murtha P. Translational control mediated by eukaryotic initiation factor-2 is restricted to specific mRNAs in transfected cells. Mol. Cell Biol. 7:1987;1568-1571.
38. Koromilas A. E., Roy S., Barber G. N., Katze M. G., Sonneberg N. Malignant transformation of the IFN-inducible dsRNA dependent protein kinase. Science. 257:1992;1685-1689.
39. Laurent A. G., Krust B., Galabru J., Svab J., Hovanessian A. G. Monoclonal antibodies to interferon induced 68,000 Mr protein and their use for the detection of double-stranded RNA dependent protein kinase in human cells. Proc. Natl. Acad. Sci. USA. 82:1985;4341-4345.
40. r. Proc. Natl. Acad. Sci. USA. 87:1990;6208-6212.
41. Lee T. G., Tang N., Thompson S., Miller J., Katze M. G. The 58,000-dalton cellular inhibitor of the interferon-induced dsRNA-activated protein kinase (PKR) is a member of the TPR repeat family of proteins. Mol. Cell. Biol. 14:1994;2331-2342.
42. Mansell C., Locarnini S. Epidemiology of hepatitis C in the east. Semin. Liver Dis. 15:1995;15-32.
43. McMillan N. A. J., Chun R. F., Siderovski D. P., Galabru J., Toone W. M., Samuel C. E., Mak T. W., Hovanessian A. G., Jeang K.-T., Williams B. R. G. HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. Virology. 213:1995;413-424.
44. Merrick W. C., Hershey J. W. B. Hershey J., Mathews M., Sonenberg N. Translational Control. 1996;31-70 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
45. Meurs E., Chong K. L., Galabru J., Thomas N., Kerr I., Williams B. R. G., Hovanessian A. G. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell. 62:1990;379-390.
46. Meurs E. F., Galabru J., Barber G. N., Katze M. G., Hovanessian A. G. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA. 90:1993;232-236.
47. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 73:1992;673-679.
48. Patel R. C., Stanton P., McMillan N. M. J., Williams B. R. G., Sen G. C. The interferon-inducible double-stranded RNA-activated protein kinase self-associatesin vitro. Proc. Natl. Acad. Sci. USA. 92:1995;8283-8287.
49. Polyak S. J., Tang N., Wambach M., Barber G. N., Katze M. G. The p58 cellular inhibitor complexes with the interferon-induced, double-stranded RNA-dependent protein kinase, PKR, to regulate its autophosphorylation and activity. J. Biol. Chem. 271:1996;1702-1707.
50. Proud C. G. PKR: A new name and new roles. Trends Biochem. Sci. 20:1995;241-246.
51. Ray R. B., Lagging L. M., Meyer K., Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70:1996;4438-4443.
52. Romano P. R., Green S. R., Barber G. N., Mathews M. B., Hinnebusch A. G. Structural requirements for dsRNA-binding, dimerization and activation of the human eIF-2α kinase DAI in yeast. Mol. Cell Biol. 15:1995;365-378.
53. Sakamuro D., Furukawa T., Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 69:1995;3893-3896.
54. Selby M. J., Choo Q., Berger K., Kuo G., Glazer E., Eckart M., Lee C., Chien D., Kuo C., Houghton M. Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J. Gen. Virol. 74:1993;1103-1113.
55. Seliger L. S., Giantini M., Shatkin A. J. Translational effects and sequence comparisons of the three serotypes of the reovirus S4 gene. Virology. 187:1992;202-210.
56. Sen G. C., Lengyel P. The interferon system: A bird's eye view of its biochemistry. J. Biol. Chem. 267:1992;5017-5020.
57. Sen G. C., Ransohoff R. M. Interferon-induced antiviral actions and their regulation. Adv. Virus. Res. 42:1993;57.
58. Shukla D. D., Hoyne P. A., Ward C. W. Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Arch. Virol. 140:1995;1747-1761.
59. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathioneS-transferase. Gene. 67:1988;31-40.
60. I. EMBO J. 4:1985;957-964.
61. Tang N. M., Ho C. Y., Katze M. G. The 58kDa cellular inhibitor of the dsRNA-dependent protein kinase (PKR) requires the TPR 6 and DnaJ motifs to stimulate protein synthesis in vivo. J. Biol. Chem. 271:1996;28660-28666.
62. Tanji Y., Kaneko T., Satoh S., Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69:1995;3980-3986.
63. Taylor D. R., Lee S. B., Romano P. R., Marshak D. R., Hinnebusch A. G., Esteban M., Mathews M. B. Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol. Cell. Biol. 16:1996;6295-6302.
64. Taylor S. S., Knighton D. R., Zheng J., Sowadski J. M., Gibbs C. S., Zoller M. J. A template for the protein kinase family. Trends Biochem. Sci. 18:1993;84-89.